MX385243B - Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen. - Google Patents

Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.

Info

Publication number
MX385243B
MX385243B MX2016015208A MX2016015208A MX385243B MX 385243 B MX385243 B MX 385243B MX 2016015208 A MX2016015208 A MX 2016015208A MX 2016015208 A MX2016015208 A MX 2016015208A MX 385243 B MX385243 B MX 385243B
Authority
MX
Mexico
Prior art keywords
clevidipine
nanoparticles
pharmaceutical compositions
compositions containing
stabilize
Prior art date
Application number
MX2016015208A
Other languages
English (en)
Other versions
MX2016015208A (es
Inventor
Akif Emre Türeli
David C Hanley
Monika Kanter
Rajeshwar Motheram
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of MX2016015208A publication Critical patent/MX2016015208A/es
Publication of MX385243B publication Critical patent/MX385243B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende clevidipina en una suspensión acuosa estéril, físicamente estable y lista para usar, de nanopartículas que estabilizan a la clevidipina contra la formación de impurezas y es adecuada para administración parenteral.
MX2016015208A 2014-05-19 2015-05-19 Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen. MX385243B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462000119P 2014-05-19 2014-05-19
PCT/US2015/031470 WO2015179334A1 (en) 2014-05-19 2015-05-19 Clevidipine nanoparticles and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
MX2016015208A MX2016015208A (es) 2017-03-23
MX385243B true MX385243B (es) 2025-03-14

Family

ID=54554604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015208A MX385243B (es) 2014-05-19 2015-05-19 Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.

Country Status (10)

Country Link
US (2) US11737989B2 (es)
EP (1) EP3145508B1 (es)
KR (1) KR102380701B1 (es)
CN (2) CN114668740A (es)
CA (1) CA2947486C (es)
ES (1) ES2950154T3 (es)
MX (1) MX385243B (es)
PL (1) PL3145508T3 (es)
RU (1) RU2759673C2 (es)
WO (1) WO2015179334A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105796494B (zh) * 2016-04-01 2019-10-11 广东药科大学 一种含氨基酸的尼莫地平亚微乳注射液及其制备方法
CN105796490B (zh) * 2016-04-01 2019-12-10 广东药科大学 一种含氨基酸的尼莫地平注射液组合物及其制备方法
CN107281104B (zh) * 2017-05-27 2021-02-02 济南康和医药科技有限公司 一种丁酸氯维地平磷脂复合物脂质体及其制备方法
EP3804703A1 (de) * 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung eines nanopartikulären wirkstoffs
EP3884930A1 (en) 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting
WO2024246613A1 (en) * 2023-05-28 2024-12-05 Precise Biopharma Pvt Ltd A room temperature stable aqueous solution for injection of clevidipine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453523A (en) * 1993-06-16 1995-09-26 Emulsion Technology, Inc. Process for obtaining highly purified phosphatidylcholine
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
JP2009536162A (ja) * 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
EP2320740B1 (en) * 2008-08-01 2014-03-26 The Medicines Company Pharmaceutical compositions of clevidipine and methods for producing low impurity concentrations of the same
US8679344B2 (en) * 2008-12-17 2014-03-25 Cerion Technology, Inc. Process for solvent shifting a nanoparticle dispersion
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
KR101823706B1 (ko) * 2010-03-22 2018-01-30 인스틸로 게엠베하 마이크로입자 또는 나노입자의 제조 방법 및 제조 장치
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
DK2627173T4 (en) * 2010-10-12 2018-10-22 Chiesi Farm Spa CLEVIDIPINE EMULSUM FORMULATIONS CONTAINING ANTIMICROBIANTS
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
US9446032B2 (en) 2011-08-26 2016-09-20 Wockhardt Limited Methods for treating cardiovascular disorders
CA2925687A1 (en) * 2012-09-27 2014-04-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
EP2925128B1 (en) * 2012-10-26 2018-04-11 Chiesi Farmaceutici S.p.A. Methods for controlling blood pressure and reducing dyspnea in heart failure
CN103479577A (zh) * 2013-09-30 2014-01-01 山东大学 含有丁酸氯维地平的脂质纳米混悬剂及其冻干制剂

Also Published As

Publication number Publication date
CA2947486A1 (en) 2015-11-26
WO2015179334A1 (en) 2015-11-26
RU2016149538A (ru) 2018-06-20
ES2950154T3 (es) 2023-10-05
US11737989B2 (en) 2023-08-29
EP3145508B1 (en) 2023-07-05
EP3145508A4 (en) 2018-01-24
BR112016027104A2 (pt) 2018-07-10
US20230145206A1 (en) 2023-05-11
RU2759673C2 (ru) 2021-11-16
PL3145508T3 (pl) 2023-10-23
KR20170032886A (ko) 2017-03-23
KR102380701B1 (ko) 2022-03-31
EP3145508C0 (en) 2023-07-05
US20170087093A1 (en) 2017-03-30
CA2947486C (en) 2023-09-26
MX2016015208A (es) 2017-03-23
CN114668740A (zh) 2022-06-28
RU2016149538A3 (es) 2019-01-17
EP3145508A1 (en) 2017-03-29
CN106456617A (zh) 2017-02-22
US12383507B2 (en) 2025-08-12

Similar Documents

Publication Publication Date Title
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX385243B (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
UY35103A (es) Compuestos de cefem 2-sustituidos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MX2014013315A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
CL2017002034A1 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
EA201790495A1 (ru) Фармацевтические композиции длительного действия
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX376741B (es) Composición farmaceútica de sulfonamida
CL2017001077A1 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
ECSP21027009A (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
CL2017001680A1 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
EA201890911A1 (ru) Комбинация тразодона и габапентина для лечения боли